

Howard A Burris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3114216/publications.pdf>

Version: 2024-02-01

80
papers

9,490
citations

218381

26
h-index

74018

75
g-index

82
all docs

82
docs citations

82
times ranked

14508
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). <i>Clinical Breast Cancer</i> , 2022, 22, 269-278.	1.1	6
2	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	13.9	220
3	Extended <i>RAS</i> Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, e261-e269.	1.9	10
4	OncoAlert Round Table Discussions: The Global COVID-19 Experience. <i>JCO Global Oncology</i> , 2021, 7, 455-463.	0.8	6
5	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 679-686.	2.9	31
6	Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	36
7	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	5.1	178
8	A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 89-97.	1.1	6
9	Correcting the ASCO position on phase I clinical trials in cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 125-125.	12.5	12
10	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifestuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 364-372.	3.2	29
11	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
12	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	5.1	362
13	Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475.	3.4	187
14	Umbralisib, a novel PI3K δ and casein kinase-1 μ inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. <i>Lancet Oncology</i> , The, 2018, 19, 486-496.	5.1	178
15	Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. <i>Lung Cancer</i> , 2018, 117, 38-43.	0.9	3
16	Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2018, 118, 6-12.	0.9	9
17	Reply to JJ. Tao et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2451-2451.	0.8	1
18	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542.	0.8	362

#	ARTICLE	IF	CITATIONS
19	Phosphatidylinositol 3-Kinase Inhibitor Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	0.8	298
20	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1041-1048.	0.8	87
21	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2017, 18, 42-51.	5.1	412
22	A Phase II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4095-4106.	3.2	213
23	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2028-2036.	0.8	111
24	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2017, 35, 139-140.	0.8	22
25	A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. <i>European Journal of Cancer</i> , 2016, 56, 1-9.	1.3	76
26	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	0.8	149
27	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	13.9	1,390
28	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1909-1920.	6.3	3,077
29	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	0.8	203
30	Targeted therapy for gastrointestinal (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 653-653.	0.8	17
31	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 278-284.	0.8	102
32	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1133-1142.	5.1	76
33	TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 4154-4154.	0.6	20
34	Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2506-2506.	0.8	10
35	Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2512-2512.	0.8	45
36	First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2520-2520.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.. Journal of Clinical Oncology, 2015, 33, 3520-3520.	0.8	7
38	A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2015, 33, 4501-4501.	0.8	43
39	Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.. Journal of Clinical Oncology, 2015, 33, 507-507.	0.8	55
40	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. Journal of Clinical Oncology, 2015, 33, 512-512.	0.8	8
41	Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 523-523.	0.8	3
42	A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.. Journal of Clinical Oncology, 2015, 33, 5513-5513.	0.8	12
43	Clinical activity and safety profile of TGR-1202, a novel once daily PI3K $\hat{\imath}$ inhibitor, in patients with CLL and B-cell lymphoma.. Journal of Clinical Oncology, 2015, 33, 7069-7069.	0.8	4
44	MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.. Journal of Clinical Oncology, 2015, 33, TPS11111-TPS11111.	0.8	5
45	First-in-human investigation of the oral first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.. Journal of Clinical Oncology, 2015, 33, TPS2615-TPS2615.	0.8	12
46	A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.. Journal of Clinical Oncology, 2015, 33, TPS2624-TPS2624.	0.8	6
47	Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study.. Journal of Clinical Oncology, 2015, 33, 297-297.	0.8	9
48	cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).. Journal of Clinical Oncology, 2015, 33, 487-487.	0.8	6
49	Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma.. Journal of Clinical Oncology, 2015, 33, 2023-2023.	0.8	0
50	Successful Treatment With Dabrafenib (GSK2118436) in a Patient With Ganglioglioma. Journal of Clinical Oncology, 2014, 32, e98-e100.	0.8	27
51	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. Journal of Clinical Oncology, 2014, 32, 3697-3704.	0.8	173
52	TGR-1202, a Novel Once Daily PI3K $\hat{\imath}$ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. Blood, 2014, 124, 1984-1984.	0.6	14
53	Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. Cancer Biology and Therapy, 2013, 14, 340-346.	1.5	13
54	Developments in the Use of Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e99-e102.	1.8	4

#	ARTICLE	IF	CITATIONS
55	Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.. Journal of Clinical Oncology, 2013, 31, 2503-2503.	0.8	12
56	A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with nonâˆ™ small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).. Journal of Clinical Oncology, 2013, 31, 2507-2507.	0.8	8
57	Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.. Journal of Clinical Oncology, 2013, 31, 2530-2530.	0.8	19
58	Safety, pharmacokinetics, and preliminary activity of the Î±-specific PI3K inhibitor BYL719: Results from the first-in-human study.. Journal of Clinical Oncology, 2013, 31, 2531-2531.	0.8	34
59	A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2585-2585.	0.8	17
60	Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAB), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.. Journal of Clinical Oncology, 2013, 31, 3004-3004.	0.8	16
61	Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.. Journal of Clinical Oncology, 2013, 31, 3044-3044.	0.8	18
62	First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous <i>KRAS</i> wild type (WT) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8062-8062.	0.8	1
63	Phase I study of the combination of BKM120 and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM) or other refractory solid tumors.. Journal of Clinical Oncology, 2013, 31, e13045-e13045.	0.8	1
64	A phase I/IB study of paclitaxel in combination with VS-6063, a focal adhesion kinase (FAK) inhibitor, in patients (pts) with advanced ovarian cancer.. Journal of Clinical Oncology, 2013, 31, TPS2620-TPS2620.	0.8	1
65	BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR⁺, HER2⁻ advanced breast cancer.. Journal of Clinical Oncology, 2013, 31, TPS660-TPS660.	0.8	3
66	Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 3564-3564.	0.8	2
67	Results of two phase I dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422.. Journal of Clinical Oncology, 2013, 31, 2617-2617.	0.8	1
68	A community-based program for personalized cancer care using next-generation sequencing (NGS).. Journal of Clinical Oncology, 2013, 31, 11102-11102.	0.8	1
69	Phase I study of c-Met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2544-2544.	0.8	0
70	Double-blind randomized phase II trial of carboplatin and pemetrexed with or without OGX-427 in patients with previously untreated stage IV non-squamous non-small-cell lung cancer (NSCLC): The Spruce Clinical Trial.. Journal of Clinical Oncology, 2013, 31, TPS8120-TPS8120.	0.8	0
71	Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma or progressive secondary brain tumor.. Journal of Clinical Oncology, 2013, 31, 2093-2093.	0.8	0
72	Developments in the Use of Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e99-e102.	1.8	2

#	ARTICLE	IF	CITATIONS
73	KRAS subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8091-8091.	0.8	1
74	Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 558-558.	0.8	4
75	Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute.. Journal of Clinical Oncology, 2013, 31, 5513-5513.	0.8	2
76	BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).. Journal of Clinical Oncology, 2012, 30, TPS648-TPS648.	0.8	8
77	Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. Journal of Oncology Practice, 2010, 6, 133-140.	2.5	77
78	Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 2461-2461.	0.6	3
79	Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients. Blood, 2010, 116, 4015-4015.	0.6	5
80	EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 2311-2319.	0.8	884